Valuation: Sanofi

Market Cap 90.48B 1,782B 105B 85.02B 77.32B 145B 10,017B 148B 996B 390B 5,016B 393B 385B 16,670B P/E 2026 *
12x
P/E 2027 * 10.5x
Enterprise Value 102B 2,007B 118B 95.75B 87.08B 164B 11,281B 166B 1,122B 439B 5,649B 443B 433B 18,773B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.95x
Free-Float
88.34%
Yield 2026 *
5.63%
Yield 2027 * 5.96%
1 day+0.72%
1 week+0.72%
Current month+0.72%
1 month-3.08%
3 months+1.40%
6 months-5.89%
Current year-14.02%
1 week 746.3
Extreme 746.3
746.3
1 month 741
Extreme 741
795
Current year 730
Extreme 730
883
1 year 730
Extreme 730
955
3 years 718.84
Extreme 718.84
1,212
5 years 718.84
Extreme 718.84
1,212
10 years 693.5
Extreme 693.5
1,286.99
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%+0.72% - - 105B
-2.25%-0.47%+72.43%+119.36% 1,052B
-0.66%+0.43%+49.01%+50.11% 627B
-0.54%+1.39%+21.88%+63.83% 441B
-1.99%-3.32%+41.98%+34.08% 349B
-1.05%-2.81%+24.22%+34.67% 287B
-2.12%-3.67%-1.09%+3.11% 241B
-0.63%+1.04%+43.03%+59.10% 224B
-1.19%-3.41%-9.18%-52.41% 202B
+0.16%+3.87%+16.25%+73.27% 172B
Average -0.52%+0.43%+28.73%+42.79% 399.46B
Weighted average by Cap. -0.07%+0.32%+41.31%+62.03%

Financials

2026 *2027 *
Net sales 47.59B 937B 55.1B 44.72B 40.67B 76.47B 5,269B 77.73B 524B 205B 2,639B 207B 202B 8,768B 50.7B 999B 58.71B 47.65B 43.33B 81.47B 5,614B 82.81B 558B 218B 2,811B 220B 216B 9,342B
Net income 7.94B 156B 9.19B 7.46B 6.79B 12.76B 879B 12.97B 87.44B 34.19B 440B 34.52B 33.77B 1,463B 9.27B 183B 10.73B 8.71B 7.92B 14.89B 1,026B 15.13B 102B 39.89B 514B 40.28B 39.41B 1,707B
Net Debt 11.42B 225B 13.22B 10.73B 9.76B 18.34B 1,264B 18.64B 126B 49.14B 633B 49.62B 48.54B 2,103B 8.23B 162B 9.53B 7.74B 7.04B 13.23B 911B 13.45B 90.64B 35.44B 456B 35.79B 35.01B 1,517B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
75.52EUR
Average target price
94.28EUR
Spread / Average Target
+24.84%

Quarterly revenue - Rate of surprise